Advertisement

Topics

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call

19:00 EST 8 Mar 2017 | Globe Newswire

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2016 financial results will be released on Monday, March 13, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Monday, March 13, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 85861485.  The live audio webcast can be accessed via the Investor Relations’ section of the Company's website at www.apricusbio.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived webcast will remain available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development.  Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States.  RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.

 

CONTACT: Institutional / Retail Investors: Matthew Beck
         mbeck@troutgroup.com
         The Trout Group LLC
         (646) 378-2933

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...